- Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other indications
- Addition of remestemcel-L could expand Novartis respiratory portfolio by adding potential first-in-class ARDS therapy using innovative cell-based technology with platform potential
- Deal includes $50 million upfront …
Before leaving port, sailors rely on meteorological data – wind force, swell, air temperature – to help them predict weather conditions at sea and stay safe.
Drug developers at Novartis are also using data to take a look into the future. They are working with the company Cibiltech to forecast disease progression of transplant patients with the help of a computer algorithm.
With this digital tool, the team at Novartis aims to reduce the time it takes to prove that an experimental therapy is safe and effective.
The partnership is part of a larger strategy at Novartis to …
- Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIs
- ELARA results for Kymriah® in relapsed or refractory (r/r) follicular lymphoma, plus long-term JULIET data on response survival and durability at more than three years in r/r DLBCL patients
- Detailed Jakavi …
Novartis signed five virtual power purchase agreements (VPPAs), which are expected to collectively add 277 megawatts of clean power to the electrical grid. This move makes Novartis the first pharmaceutical company set to achieve …
- Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical grid
- Projects expected to address Novartis greenhouse gas emissions across its European operations, equivalent to removing approximately 113 000 passenger vehicles from the road annually1
- Agreements mark a major milestone on the Novartis environmental sustainability journey to be carbon neutral …
Novartis scientist Leila Haery likes to step away from the lab and wander in nature for perspective. While outdoors, the gene therapy expert contemplates the vastness of landscapes and their evolution over time. She’s inspired to ask new questions with the potential to shape an emerging field of medicine.
Leila’s story is the first in Making Possible, a video series about lives that have been touched by cell and gene therapy. Researchers share what it’s like to work toward …
Novartis maitained its strong position in the Dow Jones Sustainability World Index with a percentile score of 91 (vs. 87 in 2019). We are proud of our industry-leading performance in the areas of social and environmental reporting, human capital …
- Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD1,2
- Follows establishment of multi-disciplinary expert coalition and Novartis commitment to sharing data and findings with ophthalmology community
- Despite existing therapies, significant unmet need still exists for wet AMD patients; data shows around half of patients have unresolved fluid, with a third requiring monthly injections3,4
Basel, November 13, …
- Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult patients and in three age categories1,2
- Sustained LDL-C reduction with inclisiran was observed regardless of age or gender differences1,2 with two doses a year, after an initial dose and then again at three months; the overall …
Translational immunologists from the Novartis Institutes for BioMedical …